A Randomised Study Comparing Escitalopram with Venlafaxine XR in Primary Care Patients with Major Depressive Disorder
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
This 8-week, randomised, double-blind study compared the efficacy and tolerability of escitalopram to that of venlafaxine XR in primary care patients with major depressive disorder. The efficacy of escitalopram (10– 20 mg; n = 148) was similar to venlafaxine XR (75– 150 mg; n = 145), based on mean change from baseline to week 8 in Montgomery and Åsberg Depression Rating Scale total score. In ad hoc analyses, escitalopram-treated patients achieved sustained remission significantly faster than did venlafaxine-treated patients. More venlafaxine-treated patients had nausea, constipation, and increased sweating (p < 0.05). When treatment was completed after 8 weeks, significantly more venlafaxine-treated patients had discontinuation symptoms (p < 0.01). Thus escitalopram treatment was similar to venlafaxine treatment with respect to efficacy and was better tolerated by patients in primary care.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Self-citationDevelopment of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Affective disorders and suicide risk: a reexamination
Bostwick, J. M., & Pankratz, V. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.12.1925 · Cited by 878
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801
The enduring psychosocial consequences of mania and depression
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.5.720 · Cited by 658
The Role of the Primary Care Physician in Patientsʼ Adherence to Antidepressant Therapy
LIN, E. H. B., KORFF, M. V., KATON, W., BUSH, T., SIMON, G. E., WALKER, E., & ROBINSON, P. (1995) · Medical Care · doi:10.1097/00005650-199501000-00006 · Cited by 587
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice.
Bhuiyan, P. S., & Rege, N. N. (2001) · PubMed · Cited by 527
Research works printed but not linked: 1
- 10.1097/00004850-200307000-00003 · DOI · Paper page
Cited by
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,520
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
“…Keller et al, 1998; Sackeim et al, 2000; Alpert et al, 2002, 2004; Rush et al, 2003a; Bielski et al, 2004; Fava et al, 2004; Goldstein et al, 2004; Montgomery et al, 2004; Nelson et al, 2004; Perlis et al, 2004; Prudic et al, 2004; Trivedi et al, 2004a) and in pooled or meta-analyses (Lepola et…”
BackgroundStahl, S. M., Grady, M. M., Moret, C., & Briley, M. (2005) · CNS Spectrums · doi:10.1017/s1092852900019726 · Cited by 458
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
“For example one found that after just 8 weeks on venlafaxine people experienced an average of five withdrawal symptoms when they stopped taking the drug (Montgomery et al., 2004).”
BackgroundPapakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.027 · Cited by 308
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Hansen, R. A., Gartlehner, G., Lohr, K. N., Gaynes, B. N., & Carey, T. S. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-6-200509200-00006 · Cited by 255
“, 2004 (63) 293 48 71 8 Escitalopram‡, 10–20 mg/d, vs.”
ResultGartlehner, G., Gaynes, B. N., Hansen, R. A., Thieda, P., DeVeaugh-Geiss, A., Krebs, E. E., Moore, C. G., Morgan, L., & Lohr, K. N. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-10-200811180-00008 · Cited by 237
Sagen, U., Vik, T. G., Moum, T., Mørland, T., Finset, A., & Dammen, T. (2009) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2009.03.007 · Cited by 232
Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants
Khoo, A. L., Zhou, H. J., Teng, M., Lin, L., Zhao, Y. J., Soh, L. B., Mok, Y. M., Lim, B. P., & Gwee, K. P. (2015) · CNS Drugs · doi:10.1007/s40263-015-0267-6 · Cited by 228
Escitalopram Therapy for Major Depression and Anxiety Disorders
Baldwin, D. S., Reines, E. H., Guiton, C., & Weiller, E. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k089 · Cited by 228
Kennedy, S. H., Andersen, H. F., & Lam, R. W. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0615 · Cited by 216
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Escitalopram versus other antidepressive agents for depression
Cipriani, A., Santilli, C., Furukawa, T. A., Signoretti, A., Nakagawa, A., McGuire, H., Churchill, R., & Barbui, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006532.pub2 · Cited by 190
Bielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178
Bareggi, S. R., Mundo, E., Dell'Osso, B., & Altamura, A. C. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425225.3.5.741 · Cited by 178
Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs
Nemeroff, C. B., Entsuah, R., Benattia, I., Demitrack, M. A., Sloan, D. M., & Thase, M. E. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.06.027 · Cited by 183
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
Reichenpfader, U., Gartlehner, G., Morgan, L. C., Greenblatt, A., Nussbaumer, B., Hansen, R. A., Van Noord, M., Lux, L., & Gaynes, B. N. (2014) · Drug Safety · doi:10.1007/s40264-013-0129-4 · Cited by 160
“we used data from 21 RCTs [63-83] providing sex-specific rates of sexual dysfunction”
Does Study Design Influence Outcome?
Rutherford, B. R., Sneed, J. R., & Roose, S. P. (2009) · Psychotherapy and Psychosomatics · doi:10.1159/000209348 · Cited by 158
Toward achieving optimal response: understanding and managing antidepressant side effects
Kelly, K., Posternak, M., & Jonathan, E. A. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.4/kkelly · Cited by 150
Gartlehner, G., Thieda, P., Hansen, R. A., Gaynes, B. N., DeVeaugh-Geiss, A., Krebs, E. E., & Lohr, K. N. (2008) · Drug Safety · doi:10.2165/00002018-200831100-00004 · Cited by 150
“, 2004([52]) 293 8 weeks Escitalopram 1020 Venlafaxine 75150 67 vs.”
BackgroundInfluentialEscitalopram in the treatment of major depressive disorder: A meta-analysis
Kennedy, S. H., Andersen, H. F., & Thase, M. E. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802622726 · Cited by 140
Liebowitz, M. R., Manley, A. L., Padmanabhan, S. K., Ganguly, R., Tummala, R., & Tourian, K. A. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802161923 · Cited by 134
Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs
Nemeroff, C. B., Entsuah, R., Benattia, I., Demitrack, M., Sloan, D. M., & Thase, M. E. (2010) · Focus · doi:10.1176/foc.8.4.foc592 · Cited by 126
Antidepressant Withdrawal and Rebound Phenomena
Henssler, J., Heinz, A., Brandt, L., & Bschor, T. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0355 · Cited by 50
Escitalopram: A Review of its Use in the Management of Major Depressive Disorder
Murdoch, D. R., & Keam, S. J. (2005) · Drugs · doi:10.2165/00003495-200565160-00013 · Cited by 130
Bauer, M., Tharmanathan, P., Volz, H., Moeller, H., & Freemantle, N. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-0849-0 · Cited by 137
“150 mg/d instead of the maximum between 225–375 mg/d [31]) the use of the different formulations such as the the immediate release (IR)-formulation of venlafaxine instead of the potentially better tolerated sustained release (SR), or inappropriately rapid dose escalation of venalfaxine [5, 9, 30] or comparator could h…”
Wade, A., Gembert, K., & Florea, I. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x210732 · Cited by 102
Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis
Kasper, S., Spadone, C., Verpillat, P., & Angst, J. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000194375.42589.c3 · Cited by 100
“0 (Montgomery et al., 2004) MADRS Z 18 Venlafaxine 75–150 mg 142 47 ± 14 71 29.”
BackgroundSartorius, N., Baghai, T. C., Baldwin, D. S., Barrett, B., Brand, U., Fleischhacker, W., Goodwin, G., Grunze, H., Knapp, M., Leonard, B. E., et al. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008255 · Cited by 98
“…and covert influence of the vested interests of study sponsors on results (sponsorship bias) has recently received a fair amount of attention (Healy, 2006 ; Heres et al., 2006 ; Lexchin et al., 2003 ; Lexchin and Light, 2006 ; Montgomery et al., 2004a; Perlis et al., 2005 ; Procyshyn et al., 2004).”
BackgroundKirino, E. (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s22495 · Cited by 92
“Escitalopram has also shown equivalent or superior efficacy to that of sustained-release venlafaxine (venlafaxine SR).(33,34)”
Khan, A., Bose, A., Alexopoulos, G. S., Gommoll, C., Li, D., & Gandhi, C. C. (2007) · Clinical Drug Investigation · doi:10.2165/00044011-200727070-00005 · Cited by 97
Brecht, S., & Courtecuisse, C. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1110 · Cited by 89
A systematic review of duloxetine and venlafaxine in major depression, including unpublished data
Schueler, Y. ‐., Koesters, M., Wieseler, B., Grouven, U., Kromp, M., Kerekes, M. F., Kreis, J., Kaiser, T., Becker, T., & Weinmann, S. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01599.x · Cited by 87
Yevtushenko, V. Y., Belous, A., Yevtushenko, Y. G., Gusinin, S. E., Buzik, O. Z., & Agibalova, T. V. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.11.014 · Cited by 83
Effect of Age, Weight, and CYP2C19 Genotype on Escitalopram Exposure
Jin, Y., Pollock, B. G., Frank, E., Cassano, G. B., Rucci, P., Müller, D. J., Kennedy, J. L., Forgione, R. N., Kirshner, M. A., Kepple, G., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337946 · Cited by 80
Escitalopram: A Review of its Use in the Management of Major Depressive Disorder in Adults
Garnock-Jones, K. P., & McCormack, P. L. (2010) · CNS Drugs · doi:10.2165/11204760-000000000-00000 · Cited by 66
A review of the adverse effects and safety of noradrenergic antidepressants
Whiskey, E., & Taylor, D. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113492027 · Cited by 64
“The risk is greater with SNRIs than with SSRIs (Montgomery et al., 2004) and it appears to be a doserelated adverse effect (Detke et al.”
BackgroundFernández, J., Montgomery, S., & Francois, C. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523020-00007 · Cited by 75
Self-citationBaldwin, D. S., Stein, D. J., Dolberg, O. T., & Bandelow, B. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1019 · Cited by 61
Escitalopram versus venlafaxine XR in the treatment of depression
Montgomery, S. A., & Andersen, H. F. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200609000-00008 · Cited by 59
“For primary care patients, the doses were 10 or 20 mg/day escitalopram and 75 or 150 mg/day venlafaxine XR (Montgomery et al., 2004).”
BackgroundMethodResultInfluentialSelf-citationRe-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis
Weinmann, S., Becker, T. M., & Koesters, M. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0975-9 · Cited by 64
“9 in the escitalopram group (Montgomery et al. 2004), patients in another study had a baseline HAM-D (17-item version) of 29.”
BackgroundMethodInfluentialWhy do we need new and better antidepressants?
Montgomery, S. A. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000199455.39552.1c · Cited by 59
“Escitalopram has been shown to have an early sustained response and early sustained remission compared to venlafaxine in a single study carried out in primary care where the doses of both drugs were modest (Montgomery et al., 2004a).”
BackgroundResultSelf-citationBaseline severity of depression predicts antidepressant drug response relative to escitalopram
Kilts, C. D., Wade, A. G., Andersen, H. F., & Schlaepfer, T. E. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902849258 · Cited by 58
“2 [42] PC.”
Manber, R., Kraemer, H. C., Arnow, B. A., Trivedi, M. H., Rush, A. J., Thase, M. E., Rothbaum, B. O., Klein, D. N., Kocsis, J. H., Gelenberg, A. J., et al. (2008) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.76.3.459 · Cited by 54
Baghai, T. C., Volz, H., & Möller, H. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970601003973 · Cited by 60
“In two studies of 8-week duration, escitalopram was compared with the SNRI venlafaxine (sustained release) (Bielski et al. 2004; Montgomery et al. 2004b).”
BackgroundMethodBose, A., Korotzer, A., Gommoll, C., & Li, D. (2008) · Depression and Anxiety · doi:10.1002/da.20355 · Cited by 53
“Earlier comparative trials of these agents in depression provided evidence that escitalopram is better tolerated than venlafaxine XR [Bielski et al., 2004; Montgomery et al., 2004].”
BackgroundResultMachado, M., & Einarson, T. R. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01050.x · Cited by 52
Prospective studies of adverse events related to antidepressant discontinuation.
Fava, M. (2006) · PubMed · Cited by 65
Vis, P., van Baardewijk, M., & Einarson, T. R. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1g076 · Cited by 56
Escitalopram for the treatment of major depression and anxiety disorders
Höschl, C., & Švestka, J. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.4.537 · Cited by 50
Escitalopram: A Review of its Use in the Management of Anxiety Disorders
Dhillon, S., Scott, L. J., & Plosker, G. L. (2006) · CNS Drugs · doi:10.2165/00023210-200620090-00010 · Cited by 47
Evidence based review of escitalopram in treating major depressive disorder in primary care
Einarson, T. R. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000139342.22133.77 · Cited by 47
“…treated 8 weeks Norway Sweden 43 ± 12 72.1 Placebo Once a day, doubled at week NA MADRS 28.7 ± 4.0 Switzerland 4 or week 6 if needed; CGI-S 4.22 UK treated 8 weeks Montgomery et al. (2004) Denmark 49 ± 15 73 DSM-IV Escitalopram 10 or 20 mg, titrated; 12.1 MADRS 28.7 ± 5.0 MADRS > 18 treated…”
InfluentialKaichi, Y., Okada, G., Takamura, M., Toki, S., Akiyama, Y., Higaki, T., Matsubara, Y., Okamoto, Y., Yamawaki, S., & Awai, K. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.12.062 · Cited by 47
“As its enhanced efficacy is not associated with an exacerbation of side effects, it yields a favorable benefit-risk ratio (Bielski et al., 2004; Burke et al., 2002; Montgomery et al., 2004).”
Demyttenaere, K., Hemels, M. E. H., Hudry, J., & Annemans, L. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.01.001 · Cited by 47
Avigan, M. I., Bjornsson, E. S., Pasanen, M., Cooper, C., Andrade, R. J., Watkins, P. B., Lewis, J. H., & Merz, M. (2014) · Drug Safety · doi:10.1007/s40264-014-0183-6 · Cited by 42
Papakostas, G. I., & Larsen, K. G. (2010) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-010-0149-3 · Cited by 45
Bradley, A. J., & Lenox‐Smith, A. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113494937 · Cited by 48
“One RCT restricted the dose of venlafaxine to 75–150 mg/day while allowing flexible dosing of escitalopram 10–20 mg/day (Montgomery et al., 2004) and the other included a fixed dose force titrated to 225 mg/day and 20 mg of venlafaxine and escitalopram respectively after eight days (Bielski et al.”
MethodRutherford, B. R., Cooper, T. M., Persaud, A., Brown, P. J., Sneed, J. R., & Roose, S. P. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r08267 · Cited by 40
Wade, A. G., Fernández, J., François, C., Hansen, K., Danchenko, N., & Despiégel, N. (2008) · PharmacoEconomics · doi:10.2165/00019053-200826110-00008 · Cited by 47
Llorca, P. M., & Fernandez, J.-L. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01335.x · Cited by 41
Fochtmann, L. J., & Gelenberg, A. J. (2005) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.3.1.34 · Cited by 44
“Evidence from randomized, clinical trials suggests that escitalopram is superior to placebo in the short-term treatment of depression (21), with efficacy and tolerability comparable to that of other antidepressants, including venlafaxine (22, 23) and citalopram (21, 24).”
ResultLimitations of contemporary antidepressants: tolerability.
Papakostas, G. I. (2007) · PubMed · Cited by 44
Garakani, A., Martinez, J. M., Marcus, S., Weaver, J., Rickels, K., Fava, M., & Hirschowitz, J. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328301a74c · Cited by 39
“The primary outcome measure was the score on the MADRS, with responders being defined as those achieving at least 50% decrease from baseline, whereas remission was prospectively defined as a MADRS total score r 12 at the study endpoint (Montgomery et al., 2004).”
MethodFranco-Chaves, J. A., Mateus, C. F., Luckenbaugh, D. A., Martinez, P. E., Mallinger, A. G., & Zarate, C. A. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.02.003 · Cited by 38
“, 2001), and has been reported – though not established – to be one of the fastest acting SSRIs (Gorman et al., 2002; Montgomery et al., 2004).”
BackgroundInfluentialYin, J., Song, X., Wang, C., Lin, X., & Miao, M. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05382-8 · Cited by 51
A Budget-Impact and Cost-Effectiveness Model for Second-Line Treatment of Major Depression
Malone, D. C. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.s6-a.8 · Cited by 42
Managing depressive and anxiety disorders with escitalopram
Thase, M. E. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.4.429 · Cited by 37
“In the first trial [48], which was conducted in primary care clinics, 293 out-patients were randomly assigned to 8 weeks of double-blind therapy with venlafaxine (75 – 150 mg/day; mean dose: 95 mg/day) or escitalopram (10 – 20 mg/day; mean dose: 12 mg/day).”
BackgroundMethodResultInfluentialPark, H. Y., Lee, B.-J., Kim, J., Bae, J. N., & Hahm, B. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.11.010 · Cited by 38
Afzali, H. H. A., Karnon, J. D., & Gray, J. (2012) · PharmacoEconomics · doi:10.2165/11590500-000000000-00000 · Cited by 39
“The incidence of AEs during the initial 8 weeks of treatment was derived from two RCTs of escitalopram versus venlafaxine([38,39]) and two RCTs of escitalopram versus duloxetine.”
MethodMao, P.-X., Tang, Y.-L., Jiang, F., Shu, L., Gu, X., Li, M., Qian, M., Ma, C., Mitchell, P. B., & Cai, Z.-J. (2008) · Depression and Anxiety · doi:10.1002/da.20222 · Cited by 35
Serotonin noradrenaline reuptake inhibitors: Logical evolution of antidepressant development
Montgomery, S. (2006) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500600637049 · Cited by 36
Self-citationWade, A. G., Toumi, I., & Hemels, M. E. H. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x41462 · Cited by 38
The effect of escitalopram on sleep problems in depressed patients
Lader, M., Andersen, H. F., & Bækdal, T. (2005) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.694 · Cited by 34
“This is supported by two recent studies indicating an as least as good efficacy but better tolerability of escitalopram compared with venlafaxine XR mg (Montgomery et al., 2004; Bielski et al., 2004).”
ResultDuloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors
Biglia, N., Bounous, V. E., Susini, T., Pecchio, S., Sgrò, L. G., Tuninetti, V., & Torta, R. (2016) · European Journal of Cancer Care · doi:10.1111/ecc.12484 · Cited by 37
“It seems that escitalopram is one of the best treatments for depression in terms of efficacy and acceptability, with low rates of discontinuation due to adverse (Bielski et al. 2004; Montgomery et al. 2004; Khan et al. 2007; Nierenberg et al. 2007; Wade et al. 2007; Cipriani et al. 2009; Shams et al. 2014).”
BackgroundKornstein, S. G., Li, D., Mao, Y., Larsson, S., Andersen, H. F., & Papakostas, G. I. (2009) · CNS Spectrums · doi:10.1017/s1092852900020320 · Cited by 32
The under-recognized role of dopamine in the treatment of major depressive disorder
Montgomery, S. A. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f2b3cb · Cited by 31
“duloxetine, venlafaxine and paroxetine) (Montgomery et al., 2004; Perahia et al., 2005; Van Geffen et al., 2005).”
BackgroundSelf-citationStein, D. J., & Lopez, A. G. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0071-8 · Cited by 35
Montgomery, S. A., Fava, M., Padmanabhan, S. K., J. Guico-Pabia, C., & Tourian, K. A. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832fbb5a · Cited by 27
“…some selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) has been associated with discontinuation symptoms in patients treated for major depressive disorder (MDD) (Haddad, 1997; Montgomery et al., 2004b; Perahia et al., 2005; Sir et al., 2005).”
BackgroundInfluentialSelf-citationUchida, H., Takeuchi, H., Suzuki, T., 野村, 健., Watanabe, K., & Kashima, H. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000185425.00644.41 · Cited by 24
“6% for the PAX group) than those in previous reports.(24,25,42) This good outcome might be explained by the smaller number of past depressive episodes and the relatively shorter duration of illness in our subjects, because these parameters have been associated with a better outcome.”
ResultDesvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy
Lieberman, D. Z., & Massey, S. H. (2009) · Core evidence · doi:10.2147/ce.s5998 · Cited by 30
“27 Bupropion was introduced around the time of the SSRIs.”
InfluentialSørensen, J. R., Stage, K. B., Damsbo, N., Lay, A. L., & Hemels, M. E. H. (2007) · Nordic Journal of Psychiatry · doi:10.1080/08039480701226070 · Cited by 23
Lam, R. W., Lönn, S. L., & Despiégel, N. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32833948d8 · Cited by 22
“Four studies were identified, two with venlafaxine (Bielski et al., 2004; Montgomery et al., 2004) and two with duloxetine (Khan et al.”
BackgroundLeonard, B. E., & Taylor, D. M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109349835 · Cited by 27
“…has been directly compared with that of venlafaxine XR in two randomized, double-blind studies, in a total of 484 patients, and found to be very similar (Bielski et al., 2004; Montgomery et al., 2004), but with some advantage of escitalopram in patients with severe MDD (Montgomery et al., 2006).”
BackgroundResultInfluentialWhy do some promising brain-stimulation devices fail the next steps of clinical development?
Edelmuth, R., Nitsche, M. A., Battistella, L. R., & Fregni, F. (2010) · Expert Review of Medical Devices · doi:10.1586/erd.09.64 · Cited by 21
Safer, D. J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000564 · Cited by 19
Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany
Kulp, W., von der Schulenburg, J. M. G., & Greiner, W. (2005) · The European Journal of Health Economics · doi:10.1007/s10198-005-0306-1 · Cited by 19
Drug Class Review: Second-Generation Antidepressants
Gartlehner, G., Hansen, R. A., Reichenpfader, U., Kaminski, A., Kien, C., Strobelberger, M., Noord, M. V., Thieda, P., Thaler, K. J., & Gaynes, B. N. (2011) · Cited by 17
Wu, E. Q., Greenberg, P. E., Yang, E., Yu, A. P., Ben-Hamadi, R., & Erder, M. H. (2009) · Journal of Medical Economics · doi:10.3111/13696990903093537 · Cited by 19
“Total medical services 4,410 (12,247) 1,629 (0, 312,973) 5,095 (17,741) 1,704 (0, 1,029,209) –685** –739**”
Bareš, M., Novák, T., Kopeček, M., Stopková, P., Kožený, J., & Höschl, C. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.05.002 · Cited by 17
“The response to treatment was defined as a reduction of the MADRS 50% and remission as MADRS score 12 points, as previously used in antidepressant studies [8,15,28].”
MethodManagement of depression in family medicine
Ööpik, P. (2007) · DSpace repository (University of Tartu) · Cited by 20
Using meta-regression in performing indirect-comparisons: comparing escitalopram with venlafaxine XR
Eckert, L., & Falissard, B. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x148625 · Cited by 15
Rutherford, B. R., Sneed, J. R., & Roose, S. P. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.01.031 · Cited by 13
“67 Montgomery et al. (2004) Escitalopram 8 MADRS .”
Thase, M. E., Ninan, P. T., Musgnung, J. J., & Trivedi, M. H. (2011) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.10m00979blu · Cited by 17
Getting the balance right: Established and emerging therapies for major depressive disorders
Vezmar (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s10485 · Cited by 16
Ninan, P. T., Musgnung, J., Messig, M., Buckley, G., Guico-Pabia, C. J., & Ramey, T. S. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.14m01715 · Cited by 11
Nordstrom, G., Danchenko, N., Despiégel, N., & Marteau, F. (2012) · Value in Health · doi:10.1016/j.jval.2011.09.011 · Cited by 11
Metadata
- Authors
- Montgomery, S. A., Huusom, A. K. T., & Bothmer, J.
- Affiliations
- Imperial College London (GB)
- Lundbeck (Denmark) (DK)
- Lundbeck (Germany) (DE)
- ORCID
- Montgomery, S.A.
- Venue
- Neuropsychobiology
- Publisher
- S. Karger AG
- Published
- 2004
- Volume
- 50
- Issue
- 1
- Pages
- 57-64
- ISSN
- 0302-282X (ISSN-L)
- 1423-0224
- OpenAlex
- W1996105921
- Semantic Scholar
- 0534a384a0087b65059d7d19c725f818f8d41407
- Cited by
- 168
- References
- 34
- Citations by year
- 2024: 3 · 2023: 4 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 5 · 2018: 4 · 2017: 2 · 2016: 5 · 2015: 5 · 2014: 3 · 2013: 7 · 2012: 8
- FWCI
- 12.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Neuropsychobiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- escitalopram, major depressive disorder, antidepressant efficacy, drug tolerability, primary care, sustained remission, discontinuation symptoms, nausea, sweating, constipation
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Constipation, Cyclohexanols, Delayed-Action Preparations, Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Nausea, Primary Health Care, Psychiatric Status Rating Scales, Sweating, Citalopram, Treatment Outcome, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.